Wegovy® Tablets (Oral Semaglutide) 25 mg: FDA Approval, Dosing, and What to Know

Medically authored by Joshua Silva, MD | Evidence-Based Weight Loss at Potere Health MD

What Is Oral Semaglutide (Wegovy® Tablets)?

Quick answer:Wegovy® tablets are the first FDA-approved oral form of semaglutide for chronic weight management, using a 25 mg once-daily dose to achieve weight-loss results similar to weekly injections.⁶,⁷

In December 2025, the FDA approved oral semaglutide (Wegovy® tablets) for chronic weight management in adults with obesity, or overweight with at least one weight-related condition. The approval also includes cardiovascular risk-reduction indications for certain adults with established cardiovascular disease.⁶,⁷

Unlike earlier oral semaglutide products approved only for diabetes, Wegovy® tablets follow a distinct FDA-labeled titration schedule designed to achieve therapeutic drug exposure for weight loss.²,⁶

Why Was Oral Wegovy® FDA-Approved in 2025?

Short answer:Clinical trials showed that 25 mg oral semaglutide daily produced substantial, sustained weight loss comparable to injectable semaglutide.²

In the Phase 3 OASIS-4 trial, adults taking 25 mg oral semaglutide achieved 13.6% average weight loss over 64 weeks, approaching results seen with injectable Wegovy® in STEP-1.¹,²

Why Is Oral Semaglutide Harder to Absorb Than Injections?

Oral semaglutide faces unique pharmacologic challenges:

• Peptides are poorly absorbed in the GI tract

• Food, gastric pH, and gastric emptying affect absorption

• Bioavailability is extremely low without enhancement³,⁴

For comparison:

• Oral semaglutide bioavailability: ~1%³,⁴

• Injectable semaglutide bioavailability: ~89%⁴

To overcome this, oral semaglutide is formulated with SNAC, an absorption enhancer that enables uptake through the stomach lining.³,⁴

Oral Wegovy® vs Injectable Wegovy®: Dose, Frequency, Results

Quick comparison:

No head-to-head trials exist, but both forms achieve clinically meaningful weight loss when used as directed.¹,²

What Is the FDA-Approved Dosing Schedule for Wegovy® Tablets?

FDA-labeled titration schedule:⁶

• Days 1–30: 1.5 mg once daily

• Days 31–60: 4 mg once daily

• Days 61–90: 9 mg once daily

• Day 91 and onward: 25 mg once daily (maintenance)

Gradual titration improves tolerability and absorption.⁶

Clinical pearl: The 1.5 mg, 4 mg, and 9 mg doses are titration doses, not the doses shown to produce full weight-loss results in clinical trials. In OASIS-4, meaningful weight loss was achieved at the 25 mg maintenance dose, after titration was complete.²

Patients considering oral Wegovy® should understand:

• Early doses may produce limited weight loss

• Therapeutic benefit is expected at the 25 mg dose

• Long-term planning should account for time and cost to reach and maintain the therapeutic dose

What patients should ask:

“What dose will I be on long term, and how long does it usually take to reach the therapeutic dose?”

How Do You Take Oral Wegovy® Correctly?

For best absorption, patients should:⁶

• Take once daily in the morning, on an empty stomach

• Use water only (≤4 oz)

• Wait at least 30 minutes before eating, drinking anything else, or taking other oral medications

• Swallow tablets whole (do not crush, split, or chew)

Because absorption is highly timing-dependent, administration technique matters more with oral semaglutide than injectable forms.³,⁶

Oral Wegovy® Tablets and Oral Thyroid Medications

Can oral Wegovy® affect thyroid levels?

Yes — but only in patients taking oral thyroid medication (such as levothyroxine).

Oral Wegovy® tablets can increase absorption of levothyroxine, which may result in lower TSH levels on laboratory testing. This reflects altered medication absorption, not a change in thyroid hormone production.³,⁵,⁶

What thyroid lab changes can occur?

If levothyroxine exposure increases, labs may show:

• Lower TSH

• Occasionally higher free T4³,⁵

These findings indicate increased thyroid medication exposure, not thyroid disease.³

How should these medications be taken?

To minimize interaction:⁶

• Take oral Wegovy® first, with water only

• Wait at least 30 minutes before taking levothyroxine or other oral medications

• Recheck thyroid labs 6–8 weeks after starting oral Wegovy® or changing dosing timing

Injectable semaglutide does not share this absorption interaction.³,⁶

Key point: Oral Wegovy® affects thyroid medication absorption, not thyroid gland function.

Why Isn’t Rybelsus® Approved for Weight Loss?

Rybelsus® is FDA-approved for type 2 diabetes, not obesity, and is available only up to 14 mg daily.⁵This dose does not achieve the drug exposure required for meaningful weight loss, unlike the 25 mg dose used in Wegovy® tablet trials.²,⁵,⁶

Compounded Oral Semaglutide vs FDA-Approved Wegovy® Tablets

Not all “oral semaglutide” products are equivalent.

Compounded oral semaglutide products may:

• Vary widely in formulation and dosing

• Use sub-therapeutic doses

• Fail to achieve FDA-studied drug exposure becaues of poor oral or gastric absoprtion⁸

FDA-approved Wegovy® tablets are:

• Specifically engineered for absorption

• Supported by large, FDA-reviewed clinical trials

• Manufactured under FDA oversight²,⁶

Patients considering non-brand oral semaglutide should discuss safety, dosing expectations, cost, and clinical appropriateness with a prescribing clinician.⁸

How Do Side Effects Compare Between Oral and Injectable Semaglutide?

No direct head-to-head trials exist.¹,²

Both forms share similar side effects:

• Nausea

• Diarrhea

• Vomiting

• Constipation

• Abdominal pain

• Decreased appetite⁶

Shared warnings include:

• Thyroid C-cell tumor boxed warning

• Pancreatitis

• Gallbladder disease

• Acute kidney injury (often dehydration-related)

• Worsening diabetic retinopathy in susceptible patients⁶

Who Qualifies for Oral Wegovy® Tablets?

Adults may qualify if they have:⁶

• Obesity (BMI ≥30), or

• Overweight (BMI ≥27) with at least one weight-related condition

Coverage varies and usually requires prior authorization.

Bottom line

Oral Wegovy® tablets provide a non-injectable, FDA-approved option for chronic weight management, but require precise dosing and timing. Treatment choice should be individualized based on effectiveness, tolerability, cost, and long-term goals.¹,²,⁶

Disclaimer

This article is for educational purposes only and is not a substitute for medical advice.

About the Author

Dr. Joshua Silva, MD, is a licensed physician and Medical Director of Potere Health MD. He earned his medical degree from the University of Hawaiʻi John A. Burns School of Medicine and completed residency training in Occupational and Environmental Medicine at the University of Utah, where he also earned a master’s degree in Occupational Health. He later completed a Master of Business Administration with an emphasis in health care administration at Ohio University.

Dr. Silva specializes in evidence-based weight management, including the expert management of diarrhea and other GI side effects common with GLP-1 and GIP therapies such as semaglutide and tirzepatide. He provides in-person and virtual care for patients in Salt Lake City, St. George, and Cedar City, Utah.

Sources

1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). N Engl J Med.2021;384:989-1002.

2. OASIS-4 Investigators. Oral Semaglutide 25 mg for Weight Management. N Engl J Med. 2025.

3. FDA Clinical Pharmacology Review for Oral Semaglutide (Rybelsus). NDA 213051.

4. Granhall C, et al. Oral Semaglutide: A Review of the First Oral GLP-1 Receptor Agonist. Diabetes Ther.2020;11(6):1347-1362.

5. FDA Prescribing Information (Rybelsus®). 2024 update.

6. FDA Prescribing Information (Wegovy®). 2025 update.

7. U.S. Food and Drug Administration. FDA approval announcement for oral semaglutide (Wegovy® tablets).

8. U.S. Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss.